Change the byword at Bayer to keep pharma growth going

13 March 2018

Continued growth in Bayer’s (BAYN: DE) Pharmaceuticals unit ensured that the German life sciences group’s 2017 financial results at least had an air of respectability about them.

As it was – with a pharma sales increase of 4.3% to a total of 16.85 billion euros ($20.6 billion) helping the group’s overall revenue figure just creep upwards by 1.5% across the group to 35.02 billion euros – it was still a pretty unsatisfied Werner Baumann who addressed journalists as he presented the annual results.

Mr Baumann, the chairman of Bayer’s management board, had to try to explain declining sales in the Consumer Health and Crop Science businesses and a delay in the expected completion of the $66 billion purchase of the agrochemical company Monsanto – now not expected to happen until the second quarter of 2018, and admitted he was not happy with the group’s performance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK